Natco Pharma Ltd (NSE:NATCOPHARM)
₹ 1196.15 -4.5 (-0.37%) Market Cap: 214.17 Bil Enterprise Value: 199.39 Bil PE Ratio: 15.54 PB Ratio: 3.68 GF Score: 82/100

Q4 2023 Natco Pharma Ltd Earnings Call Transcript

May 30, 2023 / 05:30AM GMT
Release Date Price: ₹619.5 (-2.15%)
Operator

Ladies and gentlemen, good day, and welcome to the Q4 FY '23 earnings conference call of NATCO Pharma Limited Hosted line Nuvama Wealth Management. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Kunal Randeria from Nuvama Wealth Management. Thank you, and over to you, Mr. Randeria.

Kunal Randeria
Nuvama Wealth Management Limited, Research Division - Research Analyst

Thank you, Michelle, and good morning, everyone. On behalf of Nuvama Group, I welcome you all for NATCO Pharma's Q4 FY '23 Earnings Call. With us, we have NATCO Pharma's senior management team represented by Mr. Rajeev Nannapaneni, Director and Chief Executive Officer; and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences.

Over to you, Rajesh, for opening remarks.

Rajesh Chebiyam
NATCO Pharma Limited - EVP of Crop Health Sciences

Great. Thank you, Kunal. Good morning, everyone, and welcome to NATCO's conference call discussing our earnings results

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot